New therapeutic approaches to identifying molecules for opioid abuse treatment
Ended Project Grant Awarded Last action
- Award ID
- R43DA055419
- Recipient
-
Collaborations Pharmaceuticals, Inc. UEI EFJCLL37KKH3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $512,440
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Raleigh, NC 27606, USA
Award details come from USAspending.gov.
Description
- Abstract
- Collaborations pharmaceuticals INC. Is a small business focused on developing treatments for difficult to treat diseases. The ongoing overreliance on opioids for chronic pain despite their poor ability to improve function has contributed to a significant and alarming epidemic of opioid overdose deaths and addictions in recent years. Despite the overwhelming addiction crisis, few therapies exist, and with low efficacy. Thus, a critical unmet need is an effective and safe treatment for opioid abuse disorders. Recent research has suggested that psychedelics are also capable of reducing drug-dependence, including opioid abuse, and that serious adverse effects are extremely rare. This drug abuse cessation is linked to the induction of neuritogenesis and increased neuroplasticity, a hallmark of psychedelics. While the psychedelic experience and neuroplasticity induction appear interlinked, several analogs of psychedelics have been proposed which induce neuroplasticity and drug- avoidance while seemingly lacking the psychedelic experience. Although few in number, these analogs have been named "psychoplastogens" and are promising candidates for treatment of opioid drug abuse. The DE- coupling of the psychedelic experience and neuroplasticity induction is linked to receptor specificity as psychoplastogens are specific to 5HT2A. Here, we propose to use a combination of generative machine learning models with our extensive experience of supervised machine models to generate new analogs of psychedelics that will have improved 5-HT2A specificity, adme properties, and are easily synthesizable to rapidly expand the pool of known psychoplastogens, significantly increasing potential therapeutic options for opioid abuse treatment.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $256,220 | |
| Original award | $256,220 |
Quick answers
Who received award R43DA055419?
R43DA055419 was awarded to Collaborations Pharmaceuticals, Inc. by National Institute on Drug Abuse (National Institutes of Health) on April 15, 2022.
How much is award R43DA055419 worth?
$512,440 has been obligated on R43DA055419.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award